This Is MS Multiple Sclerosis Knowledge & Support Community

Phase III trial shows Gileyna significantly reduces relapses in children and adolescents with MS

A phase III Paradigms study in paediatric multiple sclerosis (MS) has met its primary end point, showing a significant reduction in the occurrence of relapses with Gileyna (also known as fingolimod) versus interferon beta-1a...Read more - http://www.ms-uk.org/phase-iii-trial-sh ... escents-ms

MSUK wrote:Phase III trial shows Gileyna significantly reduces relapses in children and adolescents with MS

A phase III Paradigms study in paediatric multiple sclerosis (MS) has met its primary end point, showing a significant reduction in the occurrence of relapses with Gileyna (also known as fingolimod) versus interferon beta-1a...Read more - http://www.ms-uk.org/phase-iii-trial-sh ... escents-ms

But does it reduce progression of disability? That's what really counts.